DK3060200T3 - Tyrosinderivater og sammensætninger dermed - Google Patents

Tyrosinderivater og sammensætninger dermed Download PDF

Info

Publication number
DK3060200T3
DK3060200T3 DK14802529.9T DK14802529T DK3060200T3 DK 3060200 T3 DK3060200 T3 DK 3060200T3 DK 14802529 T DK14802529 T DK 14802529T DK 3060200 T3 DK3060200 T3 DK 3060200T3
Authority
DK
Denmark
Prior art keywords
tyrosin
derivatives
compositions
tyrosin derivatives
Prior art date
Application number
DK14802529.9T
Other languages
Danish (da)
English (en)
Inventor
Steven Hoffman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Application granted granted Critical
Publication of DK3060200T3 publication Critical patent/DK3060200T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
DK14802529.9T 2013-10-22 2014-10-21 Tyrosinderivater og sammensætninger dermed DK3060200T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894279P 2013-10-22 2013-10-22
US14/062,194 US9585841B2 (en) 2013-10-22 2013-10-24 Tyrosine derivatives and compositions comprising them
PCT/US2014/061527 WO2015061288A1 (en) 2013-10-22 2014-10-21 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
DK3060200T3 true DK3060200T3 (da) 2021-07-12

Family

ID=52826750

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14802529.9T DK3060200T3 (da) 2013-10-22 2014-10-21 Tyrosinderivater og sammensætninger dermed

Country Status (23)

Country Link
US (2) US9585841B2 (enExample)
EP (1) EP3060200B1 (enExample)
JP (1) JP6684210B2 (enExample)
KR (1) KR102292206B1 (enExample)
CN (1) CN106232105A (enExample)
AU (1) AU2014340263B2 (enExample)
CA (1) CA2927980C (enExample)
CY (1) CY1124386T1 (enExample)
DK (1) DK3060200T3 (enExample)
ES (1) ES2879947T3 (enExample)
HR (1) HRP20210999T1 (enExample)
HU (1) HUE055110T2 (enExample)
IL (1) IL245173B (enExample)
LT (1) LT3060200T (enExample)
MX (1) MX384083B (enExample)
PH (1) PH12016500729A1 (enExample)
PL (1) PL3060200T3 (enExample)
PT (1) PT3060200T (enExample)
RS (1) RS62216B1 (enExample)
SI (1) SI3060200T1 (enExample)
SM (1) SMT202100437T1 (enExample)
WO (1) WO2015061288A1 (enExample)
ZA (1) ZA201602770B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
WO2017201217A1 (en) * 2016-05-18 2017-11-23 Tyme, Inc. Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
WO2018093820A1 (en) * 2016-11-15 2018-05-24 Tyme, Inc. Pharmaceutical compositions and methods for the treatment of cancer
MX2019006326A (es) 2016-11-30 2019-07-12 Tyme Inc Derivados de tirosina y composiciones que los comprenden.
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3060417A1 (en) * 2017-04-21 2018-10-25 Steven Hoffman Compositions and methods for treating retinopathy
WO2019018633A1 (en) * 2017-07-19 2019-01-24 Hoffman Technologies, Inc. COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
KR20190032250A (ko) * 2017-09-19 2019-03-27 주식회사 스킨큐씨 D-타이로신 또는 이를 포함하는 펩타이드를 포함하는 피부 미백용 조성물
RU2719575C1 (ru) * 2019-02-01 2020-04-21 Общество с ограниченной ответственностью "Центр ранней диагностики нейродегенеративных заболеваний (НДЗ)" Фармацевтическая композиция на основе альфа-метил-п-тирозина и способ ранней диагностики болезни Паркинсона
AU2020276605A1 (en) 2019-05-14 2022-01-20 Tyme, Inc. Compositions and methods for treating cancer
US20210106549A1 (en) * 2019-10-15 2021-04-15 Tyme, Inc. Pharmaceutical compositions and methods
CA3167918A1 (en) * 2020-01-17 2021-07-22 Tyme, Inc. Compositions and methods for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2023128791A1 (ru) * 2021-12-30 2023-07-06 Общество С Ограниченной Ответственностью "Центр Ранней Диагностики Нейродегенеративных Заболеваний" Комбинированное лекарственное средство для ранней диагностики болезни паркинсона

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
CA1108180A (en) 1976-07-21 1981-09-01 Hamao Umezawa Analogs of bestatin
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5683981A (en) 1987-05-22 1997-11-04 Competitive Technologies, Inc. Cyclic bridged analogs of α-MSH and methods thereof
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
US4806360A (en) * 1987-10-23 1989-02-21 Advanced Polymer Systems Synthetic melanin aggregates
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
JPH02286602A (ja) * 1989-04-28 1990-11-26 Nippon Tokushu Noyaku Seizo Kk 徐放性農薬粒剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
CA2154750A1 (en) * 1992-11-19 1994-05-26 Lessek J. Wolfram Compositions and methods for temporarily coloring hair using solubilized melanin
GB2290379A (en) 1993-03-04 1995-12-20 Mini Agriculture & Fisheries Selective binding materials and assays
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US20060052319A9 (en) * 2000-04-03 2006-03-09 Sudhir Agrawal Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
US20030114362A1 (en) 2001-06-08 2003-06-19 Novaspin Biotech Gmbh Penta-or tetrapeptide binding to somatostatin receptors and the use of the same
AU2002359855B2 (en) * 2001-12-21 2008-08-21 David S. Soane Use of oligomers and polymers for drug solublization, stabilization, and delivery
US8620406B2 (en) * 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
EP1718145A4 (en) * 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
EP1768692B8 (en) * 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
EP1700598B1 (en) 2005-03-11 2009-05-13 GPC Biotech AG Anti-proliferative combination therapy comprising satraplatin or JM118 and docetaxel
CA2601304C (en) 2005-03-11 2010-08-17 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
WO2006107903A2 (en) * 2005-04-01 2006-10-12 Intezyne Technologies, Incorporated Polymeric micelles for drug delivery
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
KR20090014164A (ko) 2006-04-19 2009-02-06 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
CN101138634A (zh) * 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
FR2918990B1 (fr) * 2007-07-20 2012-12-21 Innov Ia Procede de preparation de compositions pulverulentes stables
WO2009054001A1 (en) 2007-10-22 2009-04-30 Biocon Limited A pharmaceutical composition and a process thereof
EP2262522A1 (en) 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
EP2106806A1 (en) * 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
WO2009131631A1 (en) 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
KR101078302B1 (ko) * 2008-05-29 2011-10-31 (주)프로넥스 약물전달체
US20110200556A1 (en) 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
WO2011112576A1 (en) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microspheres for sustained release of octreotide acetate
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
SMT201900024T1 (it) 2012-01-17 2019-05-10 Tyme Inc Terapia combinata per il trattamento di cancro
US9724657B2 (en) * 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
LT3060200T (lt) 2021-08-25
SI3060200T1 (sl) 2021-11-30
KR102292206B1 (ko) 2021-08-24
HUE055110T2 (hu) 2021-10-28
US11058638B2 (en) 2021-07-13
US20170172924A1 (en) 2017-06-22
WO2015061288A1 (en) 2015-04-30
NZ719457A (en) 2021-02-26
US9585841B2 (en) 2017-03-07
CA2927980A1 (en) 2015-04-30
IL245173B (en) 2020-10-29
PT3060200T (pt) 2021-07-07
PH12016500729A1 (en) 2016-05-30
ES2879947T3 (es) 2021-11-23
PL3060200T3 (pl) 2021-10-11
JP6684210B2 (ja) 2020-04-22
JP2016534071A (ja) 2016-11-04
SMT202100437T1 (it) 2021-09-14
MX2016005166A (es) 2016-12-14
CA2927980C (en) 2022-07-19
CY1124386T1 (el) 2022-07-22
EP3060200B1 (en) 2021-05-26
ZA201602770B (en) 2017-04-26
AU2014340263B2 (en) 2019-11-21
MX384083B (es) 2025-03-14
AU2014340263A1 (en) 2016-05-19
IL245173A0 (en) 2016-06-30
KR20160072239A (ko) 2016-06-22
RS62216B1 (sr) 2021-09-30
CN106232105A (zh) 2016-12-14
EP3060200A1 (en) 2016-08-31
HRP20210999T1 (hr) 2021-11-26
US20150112116A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3052485T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3060200T3 (da) Tyrosinderivater og sammensætninger dermed
HRP20180817T1 (hr) Sastavi i postupci za modulaciju farnesoid-x-receptora
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
BR112015028459A2 (pt) composições e comestíveis
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
EP3004067A4 (en) FUNGICIDE COMPOSITIONS
DK2968173T3 (da) Heterocykliske forbindelser og anvendelser deraf
EP2953474A4 (en) COMPOSITIONS AND METHODS
EP2889350A4 (en) ADHESIVE COMPOSITION
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
DK2970132T3 (da) Argininmethyltransferaseinhibitorer og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
EP2970569A4 (en) PERSISTENT CARBENE AND COMPOSITIONS WITH IT
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
PT2964616T (pt) Inibidores da neprilisina
DK3027750T3 (da) Biokatalytisk sammensætning
DK3051945T3 (da) Fungicidsammensætninger